Mn Services Vermogensbeheer B.V. Boosts Position in Pfizer Inc. $PFE

Key Points

• Mn Services Vermogensbeheer B.V. increased its stake in Pfizer by 1.7% in Q4, adding 37,611 shares to hold 2,196,611 shares valued at about $54.7 million.
• Q4 results beat: Pfizer reported $0.66 EPS versus $0.57 expected and $17.56B in revenue versus $16.93B expected, and the stock traded up roughly 2.6% on the news.
• Analyst sentiment is mixed with a consensus "Hold" and an average price target of $28.19, and institutional investors own about 68.36% of the company.

Mn Services Vermogensbeheer B.V. increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,196,611 shares of the biopharmaceutical company's stock after acquiring an additional 37,611 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Pfizer were worth $54,696,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the period. United Bank lifted its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after purchasing an additional 6,415 shares during the period. Loomis Sayles & Co. L P raised its holdings in Pfizer by 9.5% in the second quarter. Loomis Sayles & Co. L P now owns 9,152 shares of the biopharmaceutical company's stock worth $222,000 after purchasing an additional 794 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its position in Pfizer by 67.5% during the second quarter. Mackenzie Financial Corp now owns 1,414,871 shares of the biopharmaceutical company's stock valued at $34,296,000 after buying an additional 570,408 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 2.6%

Shares of NYSE:PFE opened at $27.75 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a market cap of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47. The stock's fifty day moving average price is $26.88 and its 200-day moving average price is $25.72.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer's revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Market optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and coverage by high‑profile commentators has driven short‑term buying interest — investors are revisiting Pfizer’s positioning in the obesity/GLP‑1 market. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Longer‑term bullish commentary and retail coverage argue Pfizer’s diversified portfolio, pipeline and ability to pivot (including GLP‑1 work) make it an attractive buy for patient investors. This kind of coverage can sustain inflows beyond short‑term headlines. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Inclusion on lists of large‑cap stocks with high dividends highlights Pfizer’s income appeal; dividend support can attract conservative and yield‑seeking investors amid growth uncertainty. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Spike in search and retail attention (tracked by Zacks) signals higher visibility and trading volume; increased attention can amplify moves in either direction depending on upcoming catalysts. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Consensus analyst rating remains a “Hold” (mixed buy/hold/sell split), reflecting balanced views on near‑term growth vs. pipeline uncertainty — this limits the likelihood of broad upgrades unless clinical or commercial news surprises to the upside. Pfizer Inc. NYSE: PFE Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Competitive moves from rivals — notably Eli Lilly’s large AI‑enabled drug discovery deal — underline accelerating competition and faster innovation cycles in diabetes/weight‑loss and other areas, a risk to Pfizer’s market share and margin outlook over time. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Zacks Research raised Pfizer from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 24th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an "underperform" rating in a research report on Wednesday, December 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Finally, Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the stock a "positive" rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $28.19.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.